Blinatumomab, a bispecific T-cell engager (BiTE) against CD19(scFv)/CD3(scFv), has been approved for clinical administration in refractory/relapsed B-acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL) [110]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.